ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1561

Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study

Koichi Sugihara1, Risa Wakiya2, Yusuke Ushio3, Shusaku Nakashima2, Hiromi Shimada2, Taichi Miyagi4, Kanako Chujo5, Ryoko Kagawa3, Hayamasa Yamaguchi3, Tomohiro Kameda2 and Hiroaki Dobashi6, 1Kagawa University, Miki-cho, Kita-gun, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 3Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, 4Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, 5Kagawa University, Miki, Kita District, Kagawa, Japan, 6Kagawa University, Kagawa, Japan

Meeting: ACR Convergence 2023

Keywords: Behçet's Syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Arthritis is positioned as one of the main symptoms in Behcet’s disease (BD), and it is a relatively frequent symptom that is observed in about 57% of patients in Japan. Arthritis associated with BD is considered to be important domain affecting the patient’s QOL same as oral ulcers. However, few reports have compared the clinical symptoms and QOL of BD patients with and without arthritis. This study aims to clarify the correlation between arthritis and other clinical manifestations of BD, which affect the patient’s QOL in Japanese patients with BD.

Methods: Sixty-six BD patients treated at Kagawa University Hospital for more than 6 months and who visited the hospital from January to October 2022 were included in this retrospective study. We divided these patients into with (arthritis group) or without arthritis (non-arthritis group), and evaluated clinical symptoms, disease activity, and patient quality of life. Patient’s global assessment(PGA), Evaluator’s global assessment (EGA) and Behcet’s disease current activity form (BDCAF) were used as indices of disease activity. Behcet’s disease quality of life scale (BDQOL) was used to assess patient QOL. Statistical analysis was performed using JMP® Pro 16.1.0 software (SAS Institute, Cary, NC, USA).

Results: Arthritis was observed in 48.5% of patients. No significant difference in patient characteristics was observed between two groups. Activity of arthritis in arthritis group evaluated by SDAI, CDAI and DAS-28CRP was low to moderate (Table 1). The frequency of oral ulcers were significantly higher in arthritis group than in non-arthritis group. Although skin lesions tended to be detected in arthritis group more than non-arthritis group, there was no significant difference between two groups. Among the skin domain, papulopustular lesion tended to be observed more frequently in arthritis group (Table 2). EGA and BDCAF were significantly higher in arthritis group. Although PGA and BDQOL were higher in arthritis group, the difference was not significant between two groups (Figure 1).

Conclusion: Japanese BD patients with arthritis tended to be complicated with mucocutaneous lesions. In addition, arthritis may affect overall disease activity and QOL in patients with BD, even if its activity is low to moderate. Because this study was a small, single-center, observational study, further research is needed to clarify the relationship between clinical feature and QOL in BD patients.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: K. Sugihara: None; R. Wakiya: None; Y. Ushio: None; S. Nakashima: None; H. Shimada: None; T. Miyagi: None; K. Chujo: None; R. Kagawa: None; H. Yamaguchi: None; T. Kameda: None; H. Dobashi: None.

To cite this abstract in AMA style:

Sugihara K, Wakiya R, Ushio Y, Nakashima S, Shimada H, Miyagi T, Chujo K, Kagawa R, Yamaguchi H, Kameda T, Dobashi H. Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinical-features-and-quality-of-life-of-japanese-bechets-disease-patients-with-arthritis-a-japanese-monocentric-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-features-and-quality-of-life-of-japanese-bechets-disease-patients-with-arthritis-a-japanese-monocentric-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology